HDAC1 and cancer: Another study showed that the pharmacological and transcriptional inhibition of HDAC1/3 suppressed cancer cell proliferation, altered cell morphology, and downregulated the expression of HDAC1/3 in HepG2 cells: they were treated with suberoylanilide hydroxamic acid (SAHA—broad spectrum HDAC inhibitor) and romidepsin (FK228), which induced the formation of dendritic structures and triggered apoptosis at concentrations higher than 1.00 μM.